| Full Name | Basc At Nashua |
|---|---|
| Speciality | Clinic/Center |
| Location | 15 Riverside Drive, Nashua, New Hampshire |
| Authorized Official Name and Position | Suzanna D Majewski (COO) |
| Authorized Official Contact | 6036223670 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Basc At Nashua 11 Washington Place Bedford NH 03110 Ph: (603) 622-3670 | Basc At Nashua 15 Riverside Drive Nashua NH 03062 Ph: (603) 622-3670 |
| NPI Number | 1265799092 |
|---|---|
| Provider Enumeration Date | 04/18/2012 |
| Last Update Date | 04/18/2012 |
| Medicare PECOS PAC ID | 6305099326 |
|---|---|
| Medicare Enrollment ID | O20130213000599 |
News Archive
The creation of new federal policies requiring universities to maintain detailed records about specific laboratory chemicals deemed dangerous has presents new challenges for the nation's institutions of higher education and hospitals. Fortunately, Raleigh company, EasierTech Software, has developed the solution: the country's first online database software application designed for colleges and universities that generates chemical hygiene plans, required for OSHA, and tracks the Dept. of Homeland Security's target list of chemicals.
Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients.
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations - larger-scale rearrangements of DNA that can encompass large chunks of chromosomes - disturb carefully balanced mechanisms that have evolved to regulate cell growth.
Adolor Corporation today reported a net loss of approximately $11.1 million, or ($0.24) per basic and diluted share, for the three months ended September 30, 2009 compared to a net loss of $13.3 million, or ($0.29) per basic and diluted share, for the three months ended September 30, 2008.
In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265799092 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
News Archive
The creation of new federal policies requiring universities to maintain detailed records about specific laboratory chemicals deemed dangerous has presents new challenges for the nation's institutions of higher education and hospitals. Fortunately, Raleigh company, EasierTech Software, has developed the solution: the country's first online database software application designed for colleges and universities that generates chemical hygiene plans, required for OSHA, and tracks the Dept. of Homeland Security's target list of chemicals.
Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients.
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations - larger-scale rearrangements of DNA that can encompass large chunks of chromosomes - disturb carefully balanced mechanisms that have evolved to regulate cell growth.
Adolor Corporation today reported a net loss of approximately $11.1 million, or ($0.24) per basic and diluted share, for the three months ended September 30, 2009 compared to a net loss of $13.3 million, or ($0.29) per basic and diluted share, for the three months ended September 30, 2008.
In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed.
› Verified 2 days ago
Immediate Care Of Southern New Hampshire Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 29 Northwest Blvd, Nashua, NH 03063 Phone: 603-577-2273 Fax: 603-579-5191 | |
Lamprey Health Care At Nashua Soup Kitchen And Shelter Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2 Quincy St, Nashua, NH 03060 Phone: 603-292-7292 | |
Healthy Ever After, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 505 W Hollis St, Nashua, NH 03062 Phone: 603-879-0274 Fax: 844-225-2918 | |
Passages Behavioral Health Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3 Pine Street Ext, Unit B, Nashua, NH 03060 Phone: 603-577-0665 | |
Apogee Medical Group New Hampshire Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 172 Kinsley St, Nashua, NH 03060 Phone: 603-882-3000 | |
Carol A. Pelletier Ms Aprn Dnp Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 155 Main Dunstable Rd, Suite 135, Nashua, NH 03060 Phone: 603-883-8971 |